The pharmaceutical industry is aggressively evolving, with growing demand for high-efficacy Active Pharmaceutical Ingredients (APIs). Dulaglutide, a GLP-1 receptor agonist, stands as copyrightple of this trend. To address this demand, US-based manufacturing services are emerging. These providers offer